← Back to Search

Dermal Filler

[Trial of device that is not approved or cleared by the U.S. FDA] (BILUS Trial)

N/A
Waitlist Available
Research Sponsored by Merz North America, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and week 8 post last injection, up to 12 weeks (v3)
Awards & highlights
No Placebo-Only Group

Summary

This trial studied the safety and effectiveness of a lip filler, Belotero Intense Lidocaine (BIL), to plump up thin lips.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and week 8 post last injection, up to 12 weeks (v3)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and week 8 post last injection, up to 12 weeks (v3) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Change of Treated Lips From Baseline to Visit 3 (V3), According to the Merz Lip Fullness Assessment Scale (MLFAS)
Responder Rates at V3, According to the MLFAS
Secondary study objectives
Change From Baseline in Rasch-transformed Score of the FACE-Q Satisfaction with Lips
Investigator's Global Aesthetic Improvement Scale (GAIS) Scores
Number of Subjects With Related Serious or Related Delayed-onset Treatment Emergent Adverse Events (TEAEs)
+1 more

Side effects data

From 2014 Phase 4 trial • 40 Patients • NCT01602692
40%
Nausea
10%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tumescent Solution With Dilute Epinephrine
Tumescent Solution With Dilute Lidocaine and Epinephrine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Belotero® Intense LidocaineExperimental Treatment1 Intervention
Lips injected with BIL.
Group II: Restylane® SilkActive Control1 Intervention
Lips injected with RS.

Find a Location

Who is running the clinical trial?

Merz North America, Inc.Lead Sponsor
65 Previous Clinical Trials
9,533 Total Patients Enrolled
Merz Medical ExpertStudy DirectorMerz North America, Inc.
39 Previous Clinical Trials
6,475 Total Patients Enrolled

Media Library

Belotero Intense Lidocaine (Dermal Filler) Clinical Trial Eligibility Overview. Trial Name: NCT05773066 — N/A
Condition Research Study Groups: Restylane® Silk, Belotero® Intense Lidocaine
Condition Clinical Trial 2023: Belotero Intense Lidocaine Highlights & Side Effects. Trial Name: NCT05773066 — N/A
Belotero Intense Lidocaine (Dermal Filler) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05773066 — N/A
Condition Patient Testimony for trial: Trial Name: NCT05773066 — N/A
~233 spots leftby Dec 2025